B+
Bull case
15%
Probability
Target price
$53.00
+8.2% vs current
GSK
GSKDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$45.50
-7.1% vs current
B-
Bear case
25%
Probability
Target price
$15.00
-69.4% vs current
AI sentiment snapshot
Latest data as of 2026-01-31
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+28.0
Score
AI commentary
Market snippets show mixed-to-cautious analyst views with a median below current market price, signaling modest downside in base case [#SERP-1]. Some outlets report higher individual targets near $53, creating a narrow upside band versus a wide downside distribution in lower estimates [#SERP-3][#SERP-4]. Overall tone: cautious ahead of FY2025 results with attention on post-earnings revisions.
RankAlpha Sentiment AI - 2026-01-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-02-04eventFY2025 results and guidance releaseMedium impact
GSK to report FY2025 results and any guidance updates (market pages note FY2025 results expected 2026-02-04) — market reaction likely; see consensus reporting [#SERP-4].
2026-04-30catalystPost-earnings analyst target revisionsHigh impact
Analysts historically update 1–4 weeks after results; expect target/estimate revisions and note changes to median/high/low (assumption: review window ends by 2026-04-30) — informed by analyst target aggregators [#SERP-1],[#SERP-4].
2027-01-31catalystConsensus re-rating driven by strategy/pipeline executionHigh impact
Over 12 months, successful pipeline readouts, portfolio execution or sustained sales growth could push consensus toward the high end; see GSK analyst consensus bulletin [#SERP-8].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-31 • Updated nightlySource: Internal modelMethodology